Ginkgo Bioworks reported its fourth quarter 2024 financial results on February 25, 2025, with Cell Engineering revenue growing 29% year-over-year to $34.789 million. Total revenue for Q4 2024 reached $43.847 million, an increase of 26% from Q4 2023.
For the full year 2024, total revenue was $227.043 million, a decrease of 9.7% from $251.455 million in 2023, primarily due to a decline in Biosecurity revenue. However, Cell Engineering revenue for the full year increased 21% to $173.972 million.
The company's net loss for Q4 2024 improved to $(107.534) million from $(211.694) million in Q4 2023, and full-year net loss improved to $(547.029) million from $(892.869) million in 2023. Ginkgo completed its site consolidation and continued progress on cost-cutting efforts.
As of December 31, 2024, Ginkgo held $561.572 million in cash and cash equivalents. Net cash used in operating activities for the full year 2024 was $(319.585) million.
For the full year 2025, Ginkgo issued total revenue guidance of $167 million to $187 million, with Cell Engineering revenue projected between $117 million and $137 million. Biosecurity revenue is expected to be at least $40 million, a revision down from a previous $50 million expectation, primarily due to timing uncertainties in international programs. New tools offerings are anticipated to contribute low double-digit millions in revenue for 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.